Glisten Spring 2019, out now!
The Spring 2019 edition of our magazine Glisten is out now, 60 pages packed with news and information.
FDA grants Breakthrough Therapy Designation to Amicus
The U.S. FDA has granted Breakthrough Therapy Designation to Amicus’ AT-GAA in Late Onset Pompe Disease.
Promising initial results in gene therapy trial
Dr David Weinstein reports rewarding preliminary results from the first ever gene therapy trial in a Glycogen Storage Disease.
Resistance training aids McArdle’s
A case report from the national McArdle Clinic highlights the benefits achieved through strength training with a local personal trainer.